US3638639A - Apparatus for removing lipids from the human bloodstream - Google Patents
Apparatus for removing lipids from the human bloodstream Download PDFInfo
- Publication number
- US3638639A US3638639A US13279A US3638639DA US3638639A US 3638639 A US3638639 A US 3638639A US 13279 A US13279 A US 13279A US 3638639D A US3638639D A US 3638639DA US 3638639 A US3638639 A US 3638639A
- Authority
- US
- United States
- Prior art keywords
- tube
- lipids
- lipid
- solvent
- catheter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 57
- 239000002904 solvent Substances 0.000 claims abstract description 43
- 239000000835 fiber Substances 0.000 claims abstract description 15
- 239000002250 absorbent Substances 0.000 claims abstract description 14
- 230000002745 absorbent Effects 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 13
- 210000002615 epidermis Anatomy 0.000 claims abstract description 6
- 238000012544 monitoring process Methods 0.000 claims abstract description 5
- 239000012510 hollow fiber Substances 0.000 claims description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- 229960002897 heparin Drugs 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- 238000000935 solvent evaporation Methods 0.000 claims description 6
- 229920001971 elastomer Polymers 0.000 claims description 5
- 239000000806 elastomer Substances 0.000 claims description 5
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000004945 silicone rubber Substances 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 11
- 239000005556 hormone Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 2
- 229960002455 methoxyflurane Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000011468 Albizia julibrissin Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005852 Mimosa quadrivalvis Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14525—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using microdialysis
- A61B5/14528—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using microdialysis invasively
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
Definitions
- the human bloodstream contains a wide variety of lipid and semilipid materials in trace amounts that are either accidentally ingested such as the pesticide DDT and the carcinogenic hydrocarbon 3, 4-benz [a] pyrene or are produced by the body such as regulatory hormones.
- These materials as a class are nearly insoluble in water, and are carried primarily in association with proteins of the blood plasma and in micelles in blood plasma. in many instances the concentrations of certain lipids may become excessive and cannot be removed by usual elimination processes.
- a hormone imbalance condition may exist wherein it may be desirable to administer one or more hormones to reestablish the desired balance.
- This invention provides a novel and practical apparatus for removing lipid substances such as hormones, pesticides, and carcinogens of the lipid class from circulating human blood whereby the lipid material is absorbed from the blood into the permeable wall of a lipid-absorbing catheter inserted in the bloodstream, is eluted from the wall by a continuous or pulse of solvent contained inside the catheter and is carried out of the catheter to the exterior of the body where it accumulates on surfaces from which the solvent is released by evaporation.
- the evaporating surfaces may be removed periodically for analysis and replaced by a fresh surface without surgical intervention.
- a catheter 1 made of a lipid-absorbing elastomer and sealed at one end 2 contains a hollow fiber 3 to inserted that the lower end of fiber 3 comes close to the end 2 of the silicone catheter l.
- the outer end of fiber 3 is drawn through the wall of catheter I and is connected to a system 4 for supplying solvent to the fiber 3 continuously.
- Other systems providing for pulsed, or periodic injection of solvent may be used.
- Catheter l with its contained hollow fiber 3 is inserted through the epidermis 6 into the vein 7 of a human subject by the conventional surgical procedure of venopuncture with a hollow needle of sufficient diameter to contain the catheter l.
- the catheter l and its contained hollow fiber 3 is inserted into the vein for a sufficient length, of about several centimeters, to provide contact with the flowing blood 8.
- the end 7 of catheter 1 remains outside the epidermis 6.
- a porous evaporator 9 is inserted as a plug into the catheter l.
- the evaporator 9 may take any one of several forms including a porous ceramic plug, a cellulosic wad, a suitably rolled filter paper, or any other of a variety of configurations from which solvent may be evaporated into ambient air.
- the exterior end of the hollow fiber 3 is connected to a device 4 which is a preferred embodiment of this invention is an atmospheric micropump.
- the pump 4 provides, over a period of several hours or days a carefully regulated and very small stream of solvent into the farthest interior end 2 of the catheter 1 so that the solvent issuing from the interior end of hollow fiber 3 will flow backward gradually over the interior wall of the catheter l dissolving therefrom lipid materials and carrying them out onto evaporator 9, At evaporator 9, circulating ambient air is sufficient to cause evaporation of the solvent which is in the catheter 1.
- Suitable nontoxic solvents include ethanol, diethyl ether, and anesthetics halothane, or methoxyflurane and mixtures thereof.
- a particular advantage of this apparatus is that the evaporator 9 may be removed at any time and replaced by a fresh evaporator in order that presence or absence of a particular hormone, of the ratio of hormones may be confirmed as the experiment continues.
- this device provides means for continuously monitoring the types of lipids being removed without disturbing the catheter and thereby causing pain to the subject. Therefore, it is possible to analyze accumulatively or otherwise the lipids received to evaporators 9 to enable a decision to be made as to how long the catheter should be implanted.
- lipid pesticides such as DDT or the lipid carcinogens such as 3,4-benzpyrene
- long periods of exposure of the blood to the catheter would be required to reduce effectively their concentrations in the body, although analysis to determine concentration levels in the blood can be accomplished in a relatively short time.
- Solvent is delivered at a predetermined and essentially constant rate from the chamber 10 under the force exerted by the expansion of bellows 11.
- the chamber is filled by replacing the gas therein with the liquid so while the bellows is contracted from its equilibrium position. This is accomplished conveniently by evacuating the chamber 10 and the bellows 11 to substantially zero pressure.
- the chamber is then filled with solvent by inserting the hollow fiber 3 into a solvent bath at atmospheric pressure. The solvent then proceeds through the fiber 3, and orifice 12 into chamber 10.
- the fiber is inserted into catheter l.
- the bellows is then expanded by diffusing gas from the atmosphere through tube 13 formed from an elastomeric wall and clamped at end 14. Under the force exerted by the diffused gas, the bellows expands at a substantially constant rate.
- the bellows is formed so that it exerts a substantially constant resistive force over a relatively wide subatmospheric pressure range.
- the bellows exerting a substantially constant resistive force during expansion, a slight pressure change on its inside surface effects a large change in the volume of chamber 10.
- the rate of volume change as a function of pressure change is substantially constant.
- Any structure and composition can be employed to replace the bellows I] so long as it exerts a substantially constant resistive force when expanded within its defined mechanical limits and within a pressure range between zero and atmospheric pressure.
- the rate of gas pressure increase on the expanded wall is regulated by diffusing gas through a porous barrier open to the atmosphere. The diffusion rate and consequent rate of pressure increase is regulated by the structure and composition of the diffusion barrier.
- a number of wellknown expedients may be used to the simplest of which is to incorporate into the wall of the catheter by previous admixture, anticoagulants such as heparin, capable of slow release into the adjacent blood.
- anticoagulants such as heparin
- the solvent supplied through the hollow fiber may be presaturated with heparin so that the heparin gradually diffuses through the catheter wall, at a rate necessarily very slow because of the lipid-absorbing power of this catheter wall and therefore its relative impermeability to compounds like heparin.
- any solvent that will dissolve lipid will absorb, to some extent, in a catheter wall which is capable of dissolving lipid, and therefore will enter the bloodstream at a rate determined by the surface area of the catheter, the concentration of solvent in the catheter wall and the blood flow rate next to the catheter.
- the anesthesia liquids for example diethyl ether, methoxyflurane, and halothane, are excellent solvents for hormones such as the androgens and testosterone, and are good solvents for chlorinated lipids like DDT and polynuclear aromatic hydrocarbons like 3,4 benz [a] pyrene. They are useful in this invention, singly or in combination, provided that their rate of diffusion into the bloodstream is less than that required to produce anesthesia, but as a class they powerfully swell certain elastomers such as silicone rubber, out of which the catheter might be made, and may necessitate use of very short catheter of low surface area.
- Anhydrous ethanol or ethanol at its minimum boiling azeotrope (95 percent) composition is preferred because all lipids of interest are slightly soluble in it, because it does not very rapidly diffuse through elastomers of interest into blood, and because the small quantity that does diffuse into the blood is harmless.
- Combination of ethanol with one or more anesthesia liquids give improved extraction power while not causing the degree of swelling of the catheter characteristic of the undiluted anesthesia nor the rate of diffusion into the bloodstream.
- Suitable materials from which the catheter can be formed include silicone rubbers, polyisobutylene, butadiene rubbers, butadiene-styrene copolymers or the like.
- the catheter in a preferred embodiment of this invention the catheter is made of polydimethyl siloxane gum stock by extrusion and subsequent cross-linking.
- the extruded tube having an outside diameter of approximately 1 millimeter l,000 microns) and an inside diameter of about 750 microns the end being sealed by compression of the raw extrudate prior to the cross-linking step.
- a preferred hollow fiber is made of nylon and has a diameter of approximately 500 microns outside and a diameter of approximately 200 microns inside. Nylon fibers are preferred because of their relative impermeability to ethanol, diethyl ether, and lipid materials. Thus, unwanted reextraction of the lipid into the solvent contained in the hollow fiber from the exterior solvent inside the catheter is prevented.
- Apparatus for absorbing lipid materials comprising a lipid-permeable tube closed at one end and open at the opposite end, a hollow lipid-impermeable fiber in the tube for supplying a solvent for lipids to the closed end of the tube and an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids.
- the tube comprises a lipid-permeable elastomer containing a particulate heparin blood-anticoagulant.
- An apparatus for absorbing lipid materials comprising a lipid-permeable tube closed at one end and open at the opposite end, a hollow lipid-impermeable filler in the tube for supplying a solvent for lipids to the closed end of the tube, an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids, and a pump attached to said hollow fiber for delivering solvents, continuously or periodically.
- the process for monitoring the concentration of lipids in the bloodstream of a live animal which comprises inserting into the bloodstream the closed end of a lipid-permeable tube closed at one end and open at the opposite end, said tube having a hollow lipid-impermeable fiber for supplying a solvent for lipids to the closed end of the tube and having an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids while permitting the open end of the tube to extend through the epidermis, periodically or continuously passing a solvent for lipids through the fiber into the tube and to the absorbent and periodically determining the lipid concentration on said absorbent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Materials For Medical Uses (AREA)
Abstract
A catheter for monitoring the concentration of lipids in the bloodstream made from a material that selectively absorbs lipids. The catheter is inserted in the bloodstream while the interior wall of the catheter is washed continuously or periodically with a nontoxic solvent delivered through a lipid-impermeable fiber to dissolve the absorbed lipids. The lipid-rich solvent is contacted with an absorbent located at the open end of the catheter and outside the epidermis to evaporate the solvent. The absorbent is analyzed periodically for lipids.
Description
C Unite States atent [I51 3,638,639
Merrill et al. 1 Feb. 1, 1972 [54] APPARATUS FOR REMOVING LIPIDS 2,763,266 9/1956 Evans ..l28/350 R FROM THE HUMAN BLQODSTREAM 3,572,3l5 3/l97l Cullen ..l28/2 [72] inventors: Edward W. Merrill, Cambridge, Mass; P i E i -fl h R, Chamblee Attorneyl(enway, Jenney & l-lildreth [73] Assignee: Hans H. Estin; Leonard W. Cronkhite, Jr.;
William W., trustees of The Charles Riher [57] ABSTRACT Foundation Wclbach A catheter for monitoring the concentration of lipids in the [22] Filed: Feb. 24, 1970 bloodstream made from a material that selectively absorbs lipids. The catheter is inserted in the bloodstream while the in- [21] Appl. No.. 13,279 terior wall of the catheter is washed continuously or periodically with a nontoxic solvent delivered through a lipid-im- [gi] ..128/2AF, 128/26 permeable fiber to dissove the absorbed lipids. The Piddkh I I} solvent is contacted with an absorbent locaed at the p end [58] Fleld of Search ..l28/2, 350, 2 F, 2 Ci of the catheter and outside the epidermis to evaporate h b vent. The absorbent is analyzed periodically for lipids. [56] References Cited 6 Claims, 1 Drawing Figure UNITED STATES PATENTS Kadish et al7 l2S/2 mimosa 1m: 3,638,639
INVENTOR EDWARD W. MERRILL ATTORNEYS APPARATUS FOR REMOVING LIHDS FROM THE HUMAN BLOODSTREAM This invention relates to an apparatus for selectively removing lipid materials from the bloodstream of an animal.
The human bloodstream contains a wide variety of lipid and semilipid materials in trace amounts that are either accidentally ingested such as the pesticide DDT and the carcinogenic hydrocarbon 3, 4-benz [a] pyrene or are produced by the body such as regulatory hormones. These materials as a class are nearly insoluble in water, and are carried primarily in association with proteins of the blood plasma and in micelles in blood plasma. in many instances the concentrations of certain lipids may become excessive and cannot be removed by usual elimination processes. On the other hand, a hormone imbalance condition may exist wherein it may be desirable to administer one or more hormones to reestablish the desired balance.
in the diagnosis of pregnant women or diseased humans, it is highly desirable or even essential to obtain an accurate analysis of the hormones present in trace amounts and their relative proportions. The regulatory hormones in general are found in trace concentrations of the order of parts per million. Conventional analysis for regulatory hormones requires successively taking several units of blood and extracting the hormones therefrom followed by reinfusion of the blood. This procedure is time consuming, expensive, and attended, as are all transfusions and infusions, with some hazard.
This invention provides a novel and practical apparatus for removing lipid substances such as hormones, pesticides, and carcinogens of the lipid class from circulating human blood whereby the lipid material is absorbed from the blood into the permeable wall of a lipid-absorbing catheter inserted in the bloodstream, is eluted from the wall by a continuous or pulse of solvent contained inside the catheter and is carried out of the catheter to the exterior of the body where it accumulates on surfaces from which the solvent is released by evaporation. The evaporating surfaces may be removed periodically for analysis and replaced by a fresh surface without surgical intervention.
Reference is made to the attached drawing showing one embodiment of this invention.
A catheter 1 made of a lipid-absorbing elastomer and sealed at one end 2 contains a hollow fiber 3 to inserted that the lower end of fiber 3 comes close to the end 2 of the silicone catheter l. The outer end of fiber 3 is drawn through the wall of catheter I and is connected to a system 4 for supplying solvent to the fiber 3 continuously. Other systems providing for pulsed, or periodic injection of solvent may be used.
Catheter l with its contained hollow fiber 3 is inserted through the epidermis 6 into the vein 7 of a human subject by the conventional surgical procedure of venopuncture with a hollow needle of sufficient diameter to contain the catheter l. The catheter l and its contained hollow fiber 3 is inserted into the vein for a sufficient length, of about several centimeters, to provide contact with the flowing blood 8. After insertion, the end 7 of catheter 1 remains outside the epidermis 6. A porous evaporator 9 is inserted as a plug into the catheter l. The evaporator 9 may take any one of several forms including a porous ceramic plug, a cellulosic wad, a suitably rolled filter paper, or any other of a variety of configurations from which solvent may be evaporated into ambient air.
The exterior end of the hollow fiber 3 is connected to a device 4 which is a preferred embodiment of this invention is an atmospheric micropump. The pump 4 provides, over a period of several hours or days a carefully regulated and very small stream of solvent into the farthest interior end 2 of the catheter 1 so that the solvent issuing from the interior end of hollow fiber 3 will flow backward gradually over the interior wall of the catheter l dissolving therefrom lipid materials and carrying them out onto evaporator 9, At evaporator 9, circulating ambient air is sufficient to cause evaporation of the solvent which is in the catheter 1. Suitable nontoxic solvents include ethanol, diethyl ether, and anesthetics halothane, or methoxyflurane and mixtures thereof.
Lipids circulating in the bloodstream though in vary small concentrations, upon contact with the exterior surface of the lipid-permeable catheter dissolve in it since it has a high affinity for lipids as compared to the bloodstream. However, they would accumulate in the catheter with an ever increasing concentration were it not for the elution of the lipids from the interior catheter wall by the solvent. Evaporation of the solvent at the evaporator 9 leaves the lipids there in ever increasing concentration. A particular advantage of this apparatus is that the evaporator 9 may be removed at any time and replaced by a fresh evaporator in order that presence or absence of a particular hormone, of the ratio of hormones may be confirmed as the experiment continues. State otherwise, this device provides means for continuously monitoring the types of lipids being removed without disturbing the catheter and thereby causing pain to the subject. Therefore, it is possible to analyze accumulatively or otherwise the lipids received to evaporators 9 to enable a decision to be made as to how long the catheter should be implanted.
With respect to lipid pesticides such as DDT or the lipid carcinogens such as 3,4-benzpyrene, it is likely that long periods of exposure of the blood to the catheter would be required to reduce effectively their concentrations in the body, although analysis to determine concentration levels in the blood can be accomplished in a relatively short time.
Solvent is delivered at a predetermined and essentially constant rate from the chamber 10 under the force exerted by the expansion of bellows 11. The chamber is filled by replacing the gas therein with the liquid so while the bellows is contracted from its equilibrium position. This is accomplished conveniently by evacuating the chamber 10 and the bellows 11 to substantially zero pressure. The chamber is then filled with solvent by inserting the hollow fiber 3 into a solvent bath at atmospheric pressure. The solvent then proceeds through the fiber 3, and orifice 12 into chamber 10. When the chamber is filled, the fiber is inserted into catheter l. The bellows is then expanded by diffusing gas from the atmosphere through tube 13 formed from an elastomeric wall and clamped at end 14. Under the force exerted by the diffused gas, the bellows expands at a substantially constant rate. The bellows is formed so that it exerts a substantially constant resistive force over a relatively wide subatmospheric pressure range.
By employing the bellows exerting a substantially constant resistive force during expansion, a slight pressure change on its inside surface effects a large change in the volume of chamber 10. In addition, the rate of volume change as a function of pressure change is substantially constant. By regulating the gas pressure to increase at very slow rates, liquid delivery can be effected for long periods at a substantially constant rate. Any structure and composition can be employed to replace the bellows I] so long as it exerts a substantially constant resistive force when expanded within its defined mechanical limits and within a pressure range between zero and atmospheric pressure. The rate of gas pressure increase on the expanded wall is regulated by diffusing gas through a porous barrier open to the atmosphere. The diffusion rate and consequent rate of pressure increase is regulated by the structure and composition of the diffusion barrier.
To prevent coagulation of the blood of the subject upon contact with the surface of the catheter, a number of wellknown expedients may be used to the simplest of which is to incorporate into the wall of the catheter by previous admixture, anticoagulants such as heparin, capable of slow release into the adjacent blood. Alternatively, the solvent supplied through the hollow fiber may be presaturated with heparin so that the heparin gradually diffuses through the catheter wall, at a rate necessarily very slow because of the lipid-absorbing power of this catheter wall and therefore its relative impermeability to compounds like heparin.
it is necessary to employ nontoxic solvents since any solvent that will dissolve lipid will absorb, to some extent, in a catheter wall which is capable of dissolving lipid, and therefore will enter the bloodstream at a rate determined by the surface area of the catheter, the concentration of solvent in the catheter wall and the blood flow rate next to the catheter.
For this reason powerful solvents for certain lipids like benzene, carbon disulfide, and carbon tetrachloride cannot be used at all because of their toxicity.
The anesthesia liquids, for example diethyl ether, methoxyflurane, and halothane, are excellent solvents for hormones such as the androgens and testosterone, and are good solvents for chlorinated lipids like DDT and polynuclear aromatic hydrocarbons like 3,4 benz [a] pyrene. They are useful in this invention, singly or in combination, provided that their rate of diffusion into the bloodstream is less than that required to produce anesthesia, but as a class they powerfully swell certain elastomers such as silicone rubber, out of which the catheter might be made, and may necessitate use of very short catheter of low surface area.
Anhydrous ethanol or ethanol at its minimum boiling azeotrope (95 percent) composition is preferred because all lipids of interest are slightly soluble in it, because it does not very rapidly diffuse through elastomers of interest into blood, and because the small quantity that does diffuse into the blood is harmless.
Combination of ethanol with one or more anesthesia liquids give improved extraction power while not causing the degree of swelling of the catheter characteristic of the undiluted anesthesia nor the rate of diffusion into the bloodstream.
Suitable materials from which the catheter can be formed include silicone rubbers, polyisobutylene, butadiene rubbers, butadiene-styrene copolymers or the like. in a preferred embodiment of this invention the catheter is made of polydimethyl siloxane gum stock by extrusion and subsequent cross-linking. The extruded tube having an outside diameter of approximately 1 millimeter l,000 microns) and an inside diameter of about 750 microns the end being sealed by compression of the raw extrudate prior to the cross-linking step. A preferred hollow fiber is made of nylon and has a diameter of approximately 500 microns outside and a diameter of approximately 200 microns inside. Nylon fibers are preferred because of their relative impermeability to ethanol, diethyl ether, and lipid materials. Thus, unwanted reextraction of the lipid into the solvent contained in the hollow fiber from the exterior solvent inside the catheter is prevented.
It will be understood that a constant rate of input of solvent is not essential. This device will function equally well if solvent is caused to flow through it by reason of simple capillary at traction into the evaporator 6 through the hollow fiber the other exterior end of which projects into a simple reservoir, at a rate determined by the rate of removal from the evaporation, and that periodic or pulsed injections of solvent will also effect removal of lipid. Pulsed injections of anesthesia liquids are useful in that the catheter wall is subject to periodic pulsing of its burden of lipid, while on the other hand the wall never swells with the anesthesia solvent to the same extent that it would if the perfusion were continuous.
lclaim:
1. Apparatus for absorbing lipid materials comprising a lipid-permeable tube closed at one end and open at the opposite end, a hollow lipid-impermeable fiber in the tube for supplying a solvent for lipids to the closed end of the tube and an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids.
2. The apparatus of claim I wherein the tube comprises a silicone rubber.
3. The apparatus of claim 1 wherein the tube comprises a lipid-permeable elastomer containing a particulate heparin blood-anticoagulant.
4. An apparatus for absorbing lipid materials comprising a lipid-permeable tube closed at one end and open at the opposite end, a hollow lipid-impermeable filler in the tube for supplying a solvent for lipids to the closed end of the tube, an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids, and a pump attached to said hollow fiber for delivering solvents, continuously or periodically.
5. The apparatus of claim 1 wherein the fiber is a polyamide.
6. The process for monitoring the concentration of lipids in the bloodstream of a live animal, which comprises inserting into the bloodstream the closed end of a lipid-permeable tube closed at one end and open at the opposite end, said tube having a hollow lipid-impermeable fiber for supplying a solvent for lipids to the closed end of the tube and having an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids while permitting the open end of the tube to extend through the epidermis, periodically or continuously passing a solvent for lipids through the fiber into the tube and to the absorbent and periodically determining the lipid concentration on said absorbent.
Claims (6)
1. Apparatus for absorbing lipid materials comprising a lipidpermeable tube closed at one end and open at the opposite end, a hollow lipid-impermeable fiber in the tube for supplying a solvent for lipids to the closed end of the tube and an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids.
2. The apparatus of claim 1 wherein the tube comprises a silicone rubber.
3. The apparatus of claim 1 wherein the tube comprises a lipid-permeable elastomer containing a particulate heparin blood-anticoagulant.
4. An apparatus for absorbing lipid materials comprising a lipid-permeable tube closed at one end and open at the opposite end, a hollow lipid-impermeable filler in the tube for supplying a solvent for lipids to the closed end of the tube, an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids, and a pump attached to said hollow fiber for delivering solvents, continuously or periodically.
5. The apparatus of claim 1 wherein the fiber is a polyamide.
6. The process for monitoring the concentration of lipids in the bloodstream of a live animal, which comprises inserting into the bloodstream the closed end of a lipid-permeable tube closed at one end and open at the opposite end, said tube having a hollow lipid-impermeable fiber for supplying a solvent for lipids to the closed end of the tube and having an absorbent inserted in the open end of the tube permitting solvent evaporation while retaining lipids while permitting the open end of the tube to extend through the epidermis, periodically or continuously passing a solvent for lipids through the fiber into the tube and to the absorbent and periodically determining the lipid concentration on said absorbent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1327970A | 1970-02-24 | 1970-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3638639A true US3638639A (en) | 1972-02-01 |
Family
ID=21759147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13279A Expired - Lifetime US3638639A (en) | 1970-02-24 | 1970-02-24 | Apparatus for removing lipids from the human bloodstream |
Country Status (1)
Country | Link |
---|---|
US (1) | US3638639A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3848580A (en) * | 1970-12-11 | 1974-11-19 | Hasselblad | Apparatus for controlled selective separation of undesirable constituents from blood to achieve a therapeutic effect |
US4344438A (en) * | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
US5143066A (en) * | 1990-05-08 | 1992-09-01 | University Of Pittsburgh | Optical fiber sensors for continuous monitoring of biochemicals and related method |
US6256522B1 (en) | 1992-11-23 | 2001-07-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Sensors for continuous monitoring of biochemicals and related method |
US20050261561A1 (en) * | 2004-05-24 | 2005-11-24 | Christopher W. Jones | Blood testing and therapeutic compound delivery system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2763266A (en) * | 1953-05-12 | 1956-09-18 | Sterilon Corp | Medical drainage apparatus |
US3512517A (en) * | 1964-11-30 | 1970-05-19 | Beckman Instruments Inc | Polarographic method and apparatus for monitoring blood glucose concentration |
US3572315A (en) * | 1968-11-26 | 1971-03-23 | John S Cullen | Intravascular catheter with gas-permeable tip |
-
1970
- 1970-02-24 US US13279A patent/US3638639A/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2763266A (en) * | 1953-05-12 | 1956-09-18 | Sterilon Corp | Medical drainage apparatus |
US3512517A (en) * | 1964-11-30 | 1970-05-19 | Beckman Instruments Inc | Polarographic method and apparatus for monitoring blood glucose concentration |
US3572315A (en) * | 1968-11-26 | 1971-03-23 | John S Cullen | Intravascular catheter with gas-permeable tip |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3848580A (en) * | 1970-12-11 | 1974-11-19 | Hasselblad | Apparatus for controlled selective separation of undesirable constituents from blood to achieve a therapeutic effect |
US4344438A (en) * | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
US5143066A (en) * | 1990-05-08 | 1992-09-01 | University Of Pittsburgh | Optical fiber sensors for continuous monitoring of biochemicals and related method |
US6256522B1 (en) | 1992-11-23 | 2001-07-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Sensors for continuous monitoring of biochemicals and related method |
US20050261561A1 (en) * | 2004-05-24 | 2005-11-24 | Christopher W. Jones | Blood testing and therapeutic compound delivery system |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Levy et al. | Discontinuous respiration in insects—II. The direct measurement and significance of changes in tracheal gas composition during the respiratory cycle of silkworm pupae | |
Schneiderman | Discontinuous respiration in insects: role of the spiracles | |
US5536241A (en) | Methods and devices for relaxing smooth muscle contractions | |
US3960139A (en) | Syringe device with means for removing contaminates when drawing blood sample | |
Tschirgi et al. | Slowly changing bioelectric potentials associated with the blood-brain barrier | |
US7766879B2 (en) | Flashback blood collection needle | |
AU2004322758B2 (en) | Flashback blood collection needle | |
US3649199A (en) | Method for detecting trace quantities of an organic drug material in a living animal | |
DE3850972T2 (en) | PROCESS AND SYSTEM AND MEASURING CELL ARRANGEMENT FOR THE DETERMINATION OF GLUCOSE. | |
Wenzel | Techniques in olfactometry: a critical review of the last one hundred years. | |
US3638639A (en) | Apparatus for removing lipids from the human bloodstream | |
US4136693A (en) | Constant flow I.V. device | |
WO2009110922A1 (en) | Flashback blood collection needle | |
EP0278954A1 (en) | Gas-propelled dosing device. | |
DE69838059T2 (en) | Monitor for soluble chemicals | |
Shen et al. | STUDIES ON THE DESTRUCTION OF RED BLOOD CELLS V. IRREVERSIBLY SICKLED ERYTHROCYTES: THEIR EXPERIMENTAL PRODUCTION IN VITRO | |
Grøntved et al. | Studies on gas tension in the normal middle ear: gas chromatographic analysis and a new sampling technique | |
Wald et al. | Continuous measurement of blood gases in vivo by mass spectrography | |
Deutsch et al. | Osmolality and volume factors in salt gland control of Pekin ducks after adaptation to chronic salt loading | |
CO4700313A1 (en) | METHODS FOR THE EXTRACORPORAL TREATMENT OF BLOOD, TO ADMINISTER IN AN EXTRACORPORARY FORM A CONCENTRATION OF A MEDICINAL SOLUTION IN THE BLOOD AND USEFUL DEVICES FOR SUCH ADMINISTRATION | |
Wurster et al. | Factors influencing percutaneous absorption II: absorption of methyl ethyl ketone | |
Mason et al. | Application of the saturation principle to the estimation of functional hepatic mass in normal dogs | |
Lee | Epithelial cell extrusion during fluid transport in canine small intestine. | |
Gallego et al. | The effects of blood osmolality changes on cat carotid body chemoreceptors in vivo | |
Pinard et al. | Quantitative continuous measurement of PO 2 and PCO 2 in artery and vein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CHILDREN'S MEDICAL CENTER CORPORATION THE, MASSACH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUST;REEL/FRAME:004548/0122 Effective date: 19860424 Owner name: CHILDREN'S MEDICAL CENTER CORPORATION THE, 300 LON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUST;REEL/FRAME:004548/0122 Effective date: 19860424 |